Vanda Pharmaceuticals (NASDAQ:VNDA) Earns Hold Rating from Analysts at StockNews.com

Investment analysts at StockNews.com began coverage on shares of Vanda Pharmaceuticals (NASDAQ:VNDA) in a report issued on Thursday. The brokerage set a “hold” rating on the biopharmaceutical company’s stock.

Separately, Cantor Fitzgerald increased their price target on Vanda Pharmaceuticals from $11.00 to $13.00 and gave the company an “overweight” rating in a research report on Thursday, August 1st.

Vanda Pharmaceuticals Stock Performance

Shares of NASDAQ VNDA opened at $4.69 on Thursday. The stock has a 50 day moving average price of $4.92 and a 200 day moving average price of $5.22. Vanda Pharmaceuticals has a 52 week low of $3.30 and a 52 week high of $6.75. The stock has a market capitalization of $272.95 million, a PE ratio of -58.63 and a beta of 0.77.

Vanda Pharmaceuticals (NASDAQ:VNDA) last issued its quarterly earnings results on Wednesday, July 31st. The biopharmaceutical company reported ($0.08) EPS for the quarter. Vanda Pharmaceuticals had a negative net margin of 6.00% and a negative return on equity of 2.01%. The company had revenue of $50.47 million for the quarter. As a group, research analysts forecast that Vanda Pharmaceuticals will post -0.49 EPS for the current year.

Institutional Trading of Vanda Pharmaceuticals

Hedge funds have recently made changes to their positions in the business. SageView Advisory Group LLC acquired a new stake in shares of Vanda Pharmaceuticals in the first quarter valued at approximately $34,000. Meeder Asset Management Inc. acquired a new stake in shares of Vanda Pharmaceuticals in the second quarter valued at approximately $39,000. ORG Wealth Partners LLC acquired a new stake in shares of Vanda Pharmaceuticals in the third quarter valued at approximately $40,000. SG Americas Securities LLC acquired a new stake in shares of Vanda Pharmaceuticals in the second quarter valued at approximately $61,000. Finally, Price T Rowe Associates Inc. MD lifted its position in shares of Vanda Pharmaceuticals by 18.1% in the first quarter. Price T Rowe Associates Inc. MD now owns 15,824 shares of the biopharmaceutical company’s stock valued at $66,000 after buying an additional 2,425 shares during the last quarter. 88.14% of the stock is owned by institutional investors and hedge funds.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.